Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Smoldering Multiple Myeloma 1Multiple Myeloma 1

Interventions

pembrolizumab 522Specimen Handling 383Carboplatin 375Magnetic Resonance Spectroscopy 338Cisplatin 331Nivolumab 308Cyclophosphamide 299Radiotherapy 256Paclitaxel 256Gemcitabine 236Biopsy 235Bevacizumab 215Dexamethasone 170durvalumab 167Oxaliplatin 163Capecitabine 159Rituximab 156Fluorouracil 149venetoclax 147Docetaxel 147Etoposide 142Drug Therapy 141atezolizumab 140Doxorubicin 134Ipilimumab 130Prednisone 120Radiosurgery 119Lenalidomide 119Leucovorin 113fludarabine 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leflunomide × 1 year × Clear all
NCT04508790 2026-05-29

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 2 Recruiting
29 enrolled
Plasma cell

Multiple Myeloma

NCT05014646 2026-04-30

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

City of Hope Medical Center

Phase 2 Active not recruiting
27 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡